PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5471-5480

  Adams, Sharlene ^a   Miller, Glenn T ^a   Jesson, Michael L ^a   Watanabe, Takeshi ^b   Jones, Barry ^a   Wallner, Barbara P ^a  

^a Point Therapeutics   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BORON DERIVATIVE; CD20 ANTIGEN; CHEMOKINE; CYTOKINE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; FIBROBLAST ACTIVATION PROTEIN; MESSENGER RNA; PROTEIN; RITUXIMAB; TALABOSTAT; TRASTUZUMAB; UNCLASSIFIED DRUG; VALYLBOROPROLINE;

A20 2J LYMPHOMA; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY MEDIATED CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER REGRESSION; CELLULAR IMMUNITY; CHEMOTAXIS; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EFFECTOR CELL; EL4 LYMPHOMA; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; GENE EXPRESSION REGULATION; HEMATOPOIETIC TISSUE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOID TISSUE; LYMPHOMA; MASTOCYTOMA; MELANOMA; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN BINDING; STROMA; SYNGENEIC TUMOR; T LYMPHOCYTE PRIMING; TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; TUMOR REJECTION; TUMOR XENOGRAFT; WEH1 164 FIBROSARCOMA;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD26; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHEMOKINES; COLONIC NEOPLASMS; CYTOKINES; DIPEPTIDES; DIPEPTIDYL PEPTIDASES; ENZYME INHIBITORS; FIBROSARCOMA; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA; MASTOCYTOMA; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED NOD; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 3442900472     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0447     Document Type: Article

References (51)

1. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003;33:238-44.
2. Dvorak H. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
4. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis. Cell 1991;64:327-36.
5. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
6. + T-cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
7. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14:351-62.
8. Jiang WG, Puntis MCA, Hallet MB. Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg 1994;81:1576-90.
9. Niedermeyer J, Scanlan MJ, Garin-Chesa P, et al. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int J Cancer 1997;71:383-9.
10. Aoyama A, Chen W-T. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci USA 1990;87:8296-300.
11. Jones B, Adams S, Miller GT, Lesson MI, Watanabe T, Wallner BP. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveal a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Blood 2003;102:1641-8.
12. Niedermeyer J, Enenkel B, Park JE, et al. Mouse fibroblast-activation protein: conserved Fap gene organization and biochemical function as a serine protease. Eur J Biochem 1998;254:650-4.
13. Goldstein LA, Ghersi G, Pineiro-Sanchez ML, et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta 1997;1361:11-9.
14. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25.
15. Cheng JD, Dunbrack RI, Valianou M, Rogatko A, Alpaugh K, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease in an animal model. Cancer Res 2002;62:4767-72.
16. Park JE, Lenter MC, Zimmerman RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999;274:36505-12.
17. Ghersi G, Dong H, Goldstein LA, Yeh Y, Hakkinen. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002;277:29231-41.
18. Bermpohl F, Loster K, Reutter W, Baum O. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens. FEBS Lett 1998;438:152-6.
19. aa-boroPro dipeptides. J Med Chem 1996;39:2087-94.
20. Stoppacciaro A, Melani C, Parenza M, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 1993;178:151-61.
21. Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion an improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9.
22. Bachovchin WW, Plaut AG, Flentke GR, Lynch M, Kettner CA. Inhibition of IgA1 proteinases from Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids. J Biol Chem 1990;265:3738-43.
23. Bottomly K, Davis LS, Lipsky PE. Measurement of human and murine interleukin 2 and interleukin 4. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology, Vol. 1. New York: Wiley & Sons; 1991. p. 6.3.1-12.
24. Wunderlich J, Shearer G. Assays for T-cell function. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology, Vol. 1. New York: John Wiley & Sons; 1991. p. 3.11.11-5.
25. Baggiolini M. Chemokines and leukocyte traffic. Nature (Lond.) 1998;392:565-8.
26. Miller MD, Krangel MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992;12:17-46.
27. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6.
28. Bertolini G, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferruci PF. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000;96:282-7.
29. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990;87:7235-9.
30. von Bonin A, Huhn J, Fleischer B. Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol Rev 1998;161:43-53.
31. Abal B, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
32. Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 2003;100:3611-6.
33. Fitzgerald KA, O'Neil LAJ, Gearing AJH, Callard RE. The cytokine facts book. London: Academic Press; 2001.
34. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002;14:129-35.
35. + T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 2002;168:4907-13.
36. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amirogena S. Antigen presentation and T-cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67.
37. + T-cell-mediated suppression of dendritic cells. Science (Wash. DC) 2003;299:1033-6.
38. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999;20:254-7.
39. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
40. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003;197:1537-49.
41. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis J Leukoc Biol 2000;68:1-8.
42. Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nature Immunol 2002;3:83-90.
43. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998;161:55-70.
44. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999;20:367-75.
45. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519-27.
46. Wesley UV, Tiwari S, Houghton AN. Role of dipeptidyl peptidase IV in tumor suppression of human non-small cell lung carcinoma cells. Int J Cancer 2004;109:855-66.
47. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999;190:311-22.
48. Korom S, De Meester I, Stadlbauer TH, et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997;63:1495-500.
49. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 1997;19:15-24.
50. Steinbrecher A, Reinhold D, Quigley L, et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 2001;166:2041-8.
51. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.